Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation named five new Damon Runyon Clinical Investigators at its spring 2011 Clinical Investigator Award Committee review.

22 Jun 2011

Smoking may increase risk of death from prostate cancer

Men who are diagnosed with prostate cancer and who are also smokers have an associated increased risk of all-cause, cardiovascular and prostate cancer-specific death, according to a study in the June 22/29 issue of JAMA.

22 Jun 2011

Prostate cancer risk and prevention

According to U.S. researchers smoking increases the risk that men who develop prostate cancer will die from their disease. The longer the men smoked, the greater the risk, said Stacey Kenfield of the Harvard School of Public Health in Boston, whose study appears in the Journal of the American Medical Association. Prostate cancer is the second-leading cause of cancer death in men behind lung cancer

22 Jun 2011

Caffeinated coffee boosts blood GCSF levels, protects against Alzheimer's

A yet unidentified component of coffee interacts with the beverage's caffeine, which could be a surprising reason why daily coffee intake protects against Alzheimer's disease.

22 Jun 2011

Panacea Global announces name change

Panacea Global Inc.,, a biopharmaceutical company specializing in blood (protein), serum and tissue tests to diagnose and monitor cancer, today announced the change of the Company's official trading symbol from MLXG to PANG.

20 Jun 2011

IsoRay announces combination therapy study for prostate cancer

IsoRay Inc., announced today a new dual therapy study using Cesium-131 brachytherapy (internal radiation therapy) and external beam radiation. Multiple sites have now received Institutional Review Board (IRB) approval for this study which will examine the efficacy of combining intensity modulated radiation (IMRT) with Cesium-131 brachytherapy to treat intermediate and high risk early stage prostate cancer.

20 Jun 2011

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

GTx, Inc., announced today that it initiated a Phase IIb clinical trial evaluating Capesaris, a selective estrogen receptor alpha agonist, compared to Lupron Depot for first line treatment of advanced prostate cancer.

20 Jun 2011

Novel vaccine approach for prostate cancer

Mayo Clinic investigators and collaborators from the United Kingdom cured well-established prostate tumors in mice using a human vaccine with no apparent side effects. This novel cancer treatment approach encourages the immune system to rid itself of prostate tumors without assistance from toxic chemotherapies and radiation treatments.

20 Jun 2011

Researchers use DNA library to create potential cancer vaccine

University of Leeds researchers, funded by Cancer Research UK, have used a library of DNA to create a vaccine that could be used to treat cancer, according to a study published in Nature Medicine.

20 Jun 2011

Counselling can help men overcome fears over sexual performance after prostate surgery

Men worried that prostate surgery will automatically mean an end to their sex lives are mistaken and shouldn't be put off seeking medical help, according to experts at The Prostate Centre in London.

18 Jun 2011

Cancer Statistics 2011 report finds progress has not benefitted all segments of the population equally

A steady reduction in overall cancer death rates translates to the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society.

18 Jun 2011

Study shows deprivation leads to cancer inequality in England

MORE than 2,600 deaths in England from some of the most common types of cancer could be avoided each year if all cancer patients had the same chance of survival as the most affluent section of society, a new piece of research suggests.

17 Jun 2011

USPTO issues patent for Predictive Biosciences' multiple biomarker assay

Predictive Biosciences, a provider of novel molecular diagnostic tests, announced that on June 7, 2011 the U.S. Patent and Trademark Office issued Patent Number 7,955,822 for "Detection of Nucleic Acids and Proteins".

17 Jun 2011

Researchers reveal why anti-androgen therapy may fail in men with prostate cancer

Cancer is crafty. When one avenue driving its growth is blocked by drugs targeting that path, the malignancy often creates a detour, finding an alternative route to get around the roadblock.

16 Jun 2011

DiagnoCure receives new U.S. patent for PCA3 prostate cancer biomarker portfolio

DiagnoCure, Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, today reported the issuance of a new U.S. patent, which represents a significant addition to DiagnoCure's PCA3 prostate cancer biomarker portfolio.

16 Jun 2011

Magnesium essential for absorption and metabolism of vitamin D and calcium

Magnesium deficiency is an important factor in the results obtained from vitamin D. According to Dr. Carolyn Dean, MD, ND, magnesium expert and Medical Director of the nonprofit Nutritional Magnesium Association, the effectiveness and benefits of vitamin D are greatly undermined in the absence of adequate levels of magnesium in the body.

15 Jun 2011

High proportion of men with prostate cancer die from the disease

Up to half the number of men with prostate cancer who die do so as a direct result of the disease, rather than from other causes according to a new study presented at the National Cancer Intelligence Network conference in London.

15 Jun 2011

HTX provides $750,000 funding to Profound Medical through Technology Assessment Program

HTX, a member of the Canadian Venture Capital Association, announced today it provided $750,000 in financing to Profound Medical Inc. through their Technology Assessment Program.

15 Jun 2011

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

A type of virus known as the human reovirus possesses a remarkable trait: It can replicate inside and kill cancer cells that feature a common mutation, while leaving the body's normal cells alone.

15 Jun 2011

Congress cuts critical funding for prostate cancer research

Congress is poised to ruin Father's Day for millions of men and their families by drastically cutting funding for prostate cancer research. Today, the House Appropriations Committee approved a bill that would provide $64 million in FY2012 for the Prostate Cancer Research Program as part of the Department of Defense's Congressionally Directed Medical Research Program.

15 Jun 2011